CEVEC licenses CAP® technologies for the development and commercialization of vaccines against Zika Virus infections

Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development

Cologne, Germany, February 09, 2017 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with NewLink Genetics (NASDAQ:NLNK) for use of its proprietary CAP(R)GT and CAP(R)Go cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections.

Under the terms of the agreement, CEVEC will grant NewLink Genetics and its affiliates the rights to research, develop, manufacture and commercialize CAP(R)GT and/or CAP(R)Go derived Zika vaccine candidates. Financial details of the agreement were not disclosed.

“NewLink is an important player with significant experience in developing immuno-oncology product candidates and vaccines in infectious diseases with several products in clinical development. The joint agreement is a strong endorsement of our CAP(R) system and represents another important step towards establishing CEVEC’s technologies as the new global industry standard for viral vector and vaccine development,” commented Frank Ubags, CEO of CEVEC. “Outstanding yields, scalability, excellent documentation and regulatory status, including a referenceable U.S. FDA Biologics Master File increasingly convince the biopharmaceutical industry to embark on the CAP(R) technologies. We’re proud and excited to see our technologies significantly contributing to the development of a steadily growing number of innovative gene therapy and vaccine applications including a vaccine solution that will address the threat of Zika virus disease.”

Please follow this link to read the original article.